MHC class II molecules display antigenic peptides on cell surfaces for recognition by CD4(+) T cells. Proteolysis is required in this process both for degradation of invariant chain (Ii) from class II-Ii complexes to allow subsequent binding of peptides, and for generation of the antigenic peptides. The cysteine endoprotease, cathepsin S, mediates Ii degradation in human and mouse antigen-presenting cells. Studies described here examine the functional significance of cathepsin S inhibition on antigen presentation and immunity. Specific inhibition of cathepsin S in A20 cells markedly impaired presentation of an ovalbumin epitope by interfering with class II-peptide binding, not by obstructing generation of the antigen. Administration of a cathepsin S inhibitor to mice in vivo selectively inhibited activity of cathepsin S in splenocytes, resulting in accumulation of a class II-associated Ii breakdown product, attenuation of class II-peptide complex formation, and inhibition of antigen presentation. Mice treated with inhibitor had an attenuated antibody response when immunized with ovalbumin but not the T cell-independent antigen TNP-Ficoll. In a mouse model of pulmonary hypersensitivity, treatment with the inhibitor also abrogated a rise in IgE titers and profoundly blocked eosinophilic infiltration in the lung. Thus, inhibition of cathepsin S in vivo alters Ii processing, antigen presentation, and immunity. These data identify selective inhibition of cysteine proteases as a potential therapeutic strategy for asthma and autoimmune disease processes.
R J Riese, R N Mitchell, J A Villadangos, G P Shi, J T Palmer, E R Karp, G T De Sanctis, H L Ploegh, H A Chapman
Title and authors | Publication | Year |
---|---|---|
Cysteinyl cathepsins and mast cell proteases in the pathogenesis and therapeutics of cardiovascular diseases
Y Qin, GP Shi |
Pharmacology & Therapeutics | 2011 |
Cathepsins and their endogenous inhibitors cystatins: expression and modulation in multiple sclerosis
D Haves-Zburof, T Paperna, A Gour-Lavie, I Mandel, L Glass-Marmor, A Miller |
Journal of Cellular and Molecular Medicine | 2011 |
Cysteine Cathepsins: Markers and Therapy Targets in Lung Disorders
M Kasabova, A Saidi, C Naudin, J Sage, F Lecaille, G Lalmanach |
Clinical Reviews in Bone and Mineral Metabolism | 2011 |
Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity
M Baugh, D Black, P Westwood, E Kinghorn, K McGregor, J Bruin, W Hamilton, M Dempster, C Claxton, J Cai, J Bennett, C Long, H Mckinnon, P Vink, L Hoed, M Gorecka, K Vora, E Grant, MD Percival, AM Boots, MJ Lierop |
Journal of Autoimmunity | 2011 |
Lack of cathepsin activities alter or prevent the development of lung granulomas in a mouse model of sarcoidosis
AO Samokhin, JY Gauthier, MD Percival, D Brömme |
Respiratory Research | 2011 |
The Emerging Relevance of the Cysteine Protease Cathepsin S in Disease
DM Small, RE Burden, CJ Scott |
Clinical Reviews in Bone and Mineral Metabolism | 2011 |
Microglial signalling mechanisms: Cathepsin S and Fractalkine
AK Clark, M Malcangio |
Experimental Neurology | 2011 |
Annual Reports in Medicinal Chemistry
JJ Liu, TW Lee |
Annual Reports in Medicinal Chemistry Volume 46 | 2011 |
Advances in Cancer Research
M Lemaire, S Deleu, ED Bruyne, EV Valckenborgh, E Menu, K Vanderkerken |
Advances in Cancer Research Volume 110 | 2011 |
Human blood basophils do not act as antigen-presenting cells for the major birch pollen allergen Bet v 1
C Kitzmüller, B Nagl, S Deifl, C Walterskirchen, B Jahn-Schmid, GJ Zlabinger, B Bohle |
Allergy | 2011 |
Inhibition of Cathepsin S Reduces Allogeneic T Cell Priming but Not Graft-versus-Host Disease Against Minor Histocompatibility Antigens
H Fujii, SM Ivison, H Shimizu, R Kajiwara, A Kariminia, M Yan, JP Dutz, KR Schultz |
Biology of Blood and Marrow Transplantation | 2011 |
Identification of putative cathepsin S in mangrove red snapper Lutjanus argentimaculatus and its role in antigen presentation
J Zhou, L Li, ZH Cai |
Developmental & Comparative Immunology | 2011 |
Genetic and Pharmacological Evaluation of Cathepsin S in a Mouse Model of Asthma
K Deschamps, W Cromlish, S Weicker, S Lamontagne, SL Huszar, JY Gauthier, JS Mudgett, A Guimond, R Romand, N Frossard, MD Percival, D Slipetz, CM Tan |
American journal of respiratory cell and molecular biology | 2011 |
Intraperitoneal murine Echinococcus multilocularis infection induces differentiation of TGF-β-expressing DCs that remain immature: Immature dendritic cells in chronic alveolar echinococcosis
N Mejri, J Müller, B Gottstein |
Parasite Immunology | 2011 |
Cysteine Cathepsins and the Skeleton
D Brömme |
Clinical Reviews in Bone and Mineral Metabolism | 2011 |
Cathepsin S inhibitors: 2004 – 2010
A Lee-Dutra, DK Wiener, S Sun |
Expert Opinion on Therapeutic Patents | 2011 |
CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease
F Borghese, FI Clanchy |
Expert Opinion on Therapeutic Targets | 2011 |
Extracellular Matrix Degradation
WC Parks, RP Mecham |
2011 |